140PD: LUX-Lung 7: A Phase IIb, global, randomised, open-label trial of afatinib vs gefitinib as first-line treatment for patients (pts) with advanced non-small cell lung cancer (NSCLC) harbouring activating EGFR mutations
- Park, K.
- Tan, E.-H.
- Zhang, L.
- Hirsh, V.
- O'Byrne, K.
- Boyer, M.
- Yang, J.
- Mok, T.
- Kim, M.
- Paz-Ares, L.
ISSN: 1556-1380, 1556-0864
Datum der Publikation: 2016
Ausgabe: 11
Nummer: 4
Seiten: S117-S118
Art: Artikel